<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137616</url>
  </required_header>
  <id_info>
    <org_study_id>201002003</org_study_id>
    <nct_id>NCT02137616</nct_id>
  </id_info>
  <brief_title>Antipsychotic to Treat Psychosis Syndrome</brief_title>
  <official_title>Effectiveness of Antipsychotic Drugs to Treat Psychosis Syndrome: an Open Label, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assess the safety and effects of atypical antipsychotics in subjects with
      psychosis syndrome and psychosis risk syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators investigated whether administration of atypical antipsychotics could
      alleviate prodromal symptoms and be well tolerated by subjects with psychosis syndrome and
      psychosis risk syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of PANSS total scores from baseline to 18 months</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social function</measure>
    <time_frame>18 months</time_frame>
    <description>Social function was assessed by the Global Assessment of Functioning (GAF) every three month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>18 months</time_frame>
    <description>Adverse Events were assessed at baseline and every month after treatments</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low dosage of antipsychotic drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low doseage of antipsychotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>quetiapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low doseage of antipsychotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low doseage of antipsychotic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>Risperdal tablets</description>
    <arm_group_label>risperidone</arm_group_label>
    <other_name>Risperidol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>olanzapine tablets</description>
    <arm_group_label>olanzapine</arm_group_label>
    <other_name>olanzapine tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>quetiapine tablets</description>
    <arm_group_label>quetiapine</arm_group_label>
    <other_name>quetiapine tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole tablets</description>
    <arm_group_label>aripiprazole</arm_group_label>
    <other_name>Aripiprazole tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  were help-seeking young individuals in outpatients service

          -  aged 16-30 years

          -  fitted one of the following Criteria: Psychosis-risk Syndromes (COPS-SIPS) or
             Psychotic Syndrome (POPS-SIPS) or DSM-IV diagnosis of schizophreniform disorder

        Exclusion Criteria:

          -  a previous diagnosis of any psychotic disorder or bipolar disorders according to the
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition;

          -  symptoms fully accounted for by an Axis 1 disorder or sequelae of drug/alcohol use;

          -  neurological disorders or organic disorders affecting the central nervous system,
             substance-related disorders or mental retardation as defined by the DSM-IV criteria;

          -  history treatment of antipsychotic or antidepression, mood stabilizers or
             electroconvulsive therapy;

          -  diagnosed as having a serious and unstable medical condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiaofeng Guo, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>the second xiangya hospitcal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiaofeng Guo, Dr.</last_name>
    <phone>073185554052</phone>
    <phone_ext>073185554052</phone_ext>
    <email>fengcsu@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Second Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofeng Guo, dr</last_name>
      <phone>073185554052</phone>
      <phone_ext>073185554052</phone_ext>
      <email>fengcsu@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>xiaofeng Guo, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>xiaofeng Guo</investigator_full_name>
    <investigator_title>prof.</investigator_title>
  </responsible_party>
  <keyword>psychosis</keyword>
  <keyword>syndrome</keyword>
  <keyword>risk</keyword>
  <keyword>antipsychotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

